Tags

Type your tag names separated by a space and hit enter

A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome.
Sleep Med. 2007 Nov; 8(7-8):742-52.SM

Abstract

OBJECTIVE

To assess the long-term safety and efficacy of ropinirole in the treatment of patients with restless legs syndrome (RLS) over 52 weeks.

METHODS

A 52-week, multicentre, open-label continuation study involving 310 patients, conducted in 11 countries. Eligible patients from four parent studies were invited to participate. At parent study entry, all patients had a score of > or =15 on the International Restless Legs Scale (IRLS). In this continuation study, all participants received ropinirole, 0.25-4.0 mg once daily, for 52 weeks. The primary study objective was to evaluate the safety of ropinirole. Efficacy was assessed by change in IRLS score, as well as by global improvements (clinical global impression [CGI] scale) and improvements in measures of sleep, work productivity, and quality of life.

RESULTS

Overall, 251 (81.0%) patients completed the study. The mean ropinirole dose at study end was 1.90 mg/day. A total of 282 patients (91.3%) reported > or = 1 adverse event. For the majority of patients, the reported adverse events were mild or moderate in intensity. The most common adverse event was nausea. Adverse events led to discontinuation in 8.7% of patients. At week 52, IRLS scores improved by an average of 12.0 points from baseline, and 82.8% of patients were 'much improved' or 'very much improved' on the CGI-improvement scale. Ropinirole treatment was also associated with improvements in measures of sleep and quality of life.

CONCLUSIONS

Ropinirole was well tolerated and therapeutic efficacy was maintained over 52 weeks in patients with RLS.

Authors+Show Affiliations

Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain. dgb@iis.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17512789

Citation

Garcia-Borreguero, Diego, et al. "A 52-week Open-label Study of the Long-term Safety of Ropinirole in Patients With Restless Legs Syndrome." Sleep Medicine, vol. 8, no. 7-8, 2007, pp. 742-52.
Garcia-Borreguero D, Grunstein R, Sridhar G, et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med. 2007;8(7-8):742-52.
Garcia-Borreguero, D., Grunstein, R., Sridhar, G., Dreykluft, T., Montagna, P., Dom, R., Lainey, E., Moorat, A., & Roberts, J. (2007). A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Medicine, 8(7-8), 742-52.
Garcia-Borreguero D, et al. A 52-week Open-label Study of the Long-term Safety of Ropinirole in Patients With Restless Legs Syndrome. Sleep Med. 2007;8(7-8):742-52. PubMed PMID: 17512789.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. AU - Garcia-Borreguero,Diego, AU - Grunstein,Ronald, AU - Sridhar,Guruswamy, AU - Dreykluft,Tilman, AU - Montagna,Pasquale, AU - Dom,René, AU - Lainey,Eric, AU - Moorat,Anne, AU - Roberts,James, Y1 - 2007/05/18/ PY - 2006/07/13/received PY - 2006/09/08/revised PY - 2006/09/25/accepted PY - 2007/5/22/pubmed PY - 2008/2/5/medline PY - 2007/5/22/entrez SP - 742 EP - 52 JF - Sleep medicine JO - Sleep Med. VL - 8 IS - 7-8 N2 - OBJECTIVE: To assess the long-term safety and efficacy of ropinirole in the treatment of patients with restless legs syndrome (RLS) over 52 weeks. METHODS: A 52-week, multicentre, open-label continuation study involving 310 patients, conducted in 11 countries. Eligible patients from four parent studies were invited to participate. At parent study entry, all patients had a score of > or =15 on the International Restless Legs Scale (IRLS). In this continuation study, all participants received ropinirole, 0.25-4.0 mg once daily, for 52 weeks. The primary study objective was to evaluate the safety of ropinirole. Efficacy was assessed by change in IRLS score, as well as by global improvements (clinical global impression [CGI] scale) and improvements in measures of sleep, work productivity, and quality of life. RESULTS: Overall, 251 (81.0%) patients completed the study. The mean ropinirole dose at study end was 1.90 mg/day. A total of 282 patients (91.3%) reported > or = 1 adverse event. For the majority of patients, the reported adverse events were mild or moderate in intensity. The most common adverse event was nausea. Adverse events led to discontinuation in 8.7% of patients. At week 52, IRLS scores improved by an average of 12.0 points from baseline, and 82.8% of patients were 'much improved' or 'very much improved' on the CGI-improvement scale. Ropinirole treatment was also associated with improvements in measures of sleep and quality of life. CONCLUSIONS: Ropinirole was well tolerated and therapeutic efficacy was maintained over 52 weeks in patients with RLS. SN - 1389-9457 UR - https://www.unboundmedicine.com/medline/citation/17512789/A_52_week_open_label_study_of_the_long_term_safety_of_ropinirole_in_patients_with_restless_legs_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1389-9457(06)00622-8 DB - PRIME DP - Unbound Medicine ER -